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OBJECTIVES The goal of this study was to determine the prevalence of “malignant” mutations in
hypertrophic cardiomyopathy (HCM).
BACKGROUND Previous genotype-phenotype studies have implicated four mutations (R403Q, R453C,
G716R and R719W) as highly malignant defects in the beta-myosin heavy chain (MYH7).
In the cardiac troponin T gene (TNNT2), a specific mutation (R92W) has been associated
with high risk of sudden death. Routine clinical screening for these malignant mutations has
been suggested to identify high-risk individuals.
METHODS We screened 293 unrelated individuals with HCM seen at the Mayo Clinic in Rochester,
Minnesota, between April 1997 and October 2000. Deoxyribonucleic acid (DNA) was
obtained after informed consent; amplification of MYH7 exons 13 (R403Q), 14 (R453C) and
19 (G716R and R719W), and TNNT2 exon 9 (R92W) was performed by polymerase chain
reaction. The mutations were detected using denaturing high-performance liquid chroma-
tography and automated DNA sequencing.
RESULTS The mean age at diagnosis was 42 years with 53 patients diagnosed before age 25. The mean
maximal left ventricular wall thickness was 21 mm. Nearly one-third of cases were familial
and one-fourth had a family history of sudden cardiac death. Only 3 of the 293 patients
possessed one of the five “malignant” mutations, and all 3 patients were 25 years of age at
presentation (p  0.006).
CONCLUSIONS This finding underscores the profound genetic heterogeneity in HCM. Only 1% of unrelated
individuals seen at a tertiary referral center for HCM possessed one of the five “malignant”
mutations that were examined. Routine clinical testing for these specific mutations is of low
yield. (J Am Coll Cardiol 2002;39:2042–8) © 2002 by the American College of Cardiology
Foundation
Hypertrophic cardiomyopathy (HCM) is defined as the
presence of a hypertrophied, nondilated left ventricle in the
absence of another causative disease (1). It is estimated to
affect 1 in 500 persons, with highly variable clinical and
pathologic presentations and penetrance (2,3). The severity
of disease varies from a lifelong asymptomatic course to a
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sentinel event of sudden cardiac death (SCD) at a young
age. A growing realization that the implanted cardioverter
defibrillator (ICD) is effective in the primary and secondary
prevention of SCD has provided an added impetus to
discover new approaches for the identification and risk
stratification of susceptible individuals in whom the prophy-
lactic implantation of an ICD might be life saving (4).
In addition to this phenotypic variability, there is pro-
found heterogeneity in the genetic substrate for HCM. To
date, nine genes encoding various components of the cardiac
sarcomere have been implicated in HCM: cardiac beta-
myosin heavy chain (MYH7) (5–8), troponin T (TNNT2)
(9,10), alpha tropomyosin (TPM1), myosin binding protein
C3 (MYBPC3), cardiac ventricular myosin light chain
(MYL2), cardiac myosin alkali light chain (MYL3) (11),
troponin I (TNNI3) (12), alpha cardiac actin (ACTC)
(13,14) and titin (TTN) (15). The familial HCM mutation
database lists over 150 unique mutations scattered through-
out these sarcomeric genes (16).
Despite this considerable phenotypic and genotypic di-
versity, it was hoped that through genotype-phenotype
correlative studies genetic testing would identify those
individuals at high risk for SCD to facilitate primary
prevention (17–19). Mutations in MYH7 are the most
commonly described defects in HCM and account for
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approximately 35% to 50% of all cases of familial HCM
(17,19–22). Although it is well-established that no partic-
ular clinical or prognostic phenotype is mutation specific,
four MYH7 mutations, R403Q (exon 13), R453C (exon 14)
and G716R and R719W (exon 19), have been associated
particularly with a high incidence of SCD and are consid-
ered “malignant” mutations in comparison with other
HCM-causing mutations (17,23,24). Mutations in cardiac
troponin T, particularly R92W (exon 9), have been associ-
ated with a high incidence of SCD in spite of minimal
hypertrophy (10,23).
The association between specific MYH7 and TNNT2
defects with an adverse prognosis raised the exciting possi-
bility that genotyping alone may identify individuals at high
risk of SCD and direct potentially lifesaving ICD therapy
(19,21,25). The success of genotype-phenotype correlative
studies is dependent on the interactions with modifier genes
and environmental influences, but the notion that molecular
genetic testing may direct clinical treatment persists (26,27).
Moreover, from a cost-effective standpoint, an estimation of
the prevalence of malignant mutations in the overall per-
spective of HCM is of utmost relevance. For these reasons,
we determined the prevalence of these “malignant” muta-
tions among a diverse, unselected group of patients with
HCM seen in a subspecialty clinic within a large tertiary
referral center.
METHODS
Patient population. From April 1997 through October
2000, 293 unrelated individuals seen in the Mayo Medical
Center HCM Clinic and diagnosed with HCM provided
written informed consent for genomic evaluation in this
study approved by the Mayo Foundation Institution Review
Board.
Extraction and amplification of MYH7 and TNNT2.
Genomic deoxyribonucleic acid (DNA) was extracted from
peripheral blood lymphocytes using the Purgene DNA
extraction kit from Gentra, Inc. (Minneapolis, Minnesota).
Protein-encoding exons containing the previously reported
“malignant” mutations (exons 13, 14 and 19) of the cardiac
beta-myosin heavy chain, MYH7, were amplified from
genomic DNA by polymerase chain reaction (PCR) using
the full-length genomic sequence and previously published
intron/exon-based primers (28). Exon 9 of cardiac troponin
T, TNNT2, was amplified using a forward primer designed
in our lab (5 CTAGCCCACCCATCTCTCC 3) and
the published 9R280 reverse primer sequence (5 GGAT-
GAGACAGACTGGCCATCAG 3) (29).
Mutational analysis. Sequence variations were detected by
denaturing high-performance liquid chromatography (DH-
PLC) using the Transgenomic WAVE system (Omaha,
Nebraska), as previously described (30). In brief, PCR
products were injected into the denaturing column and
eluted with increasing concentrations of acetonitrile. Ho-
mozygotes have only homoduplex DNA. Heterozygotes
form both homoduplexes and heteroduplexes. Heterodu-
plexes are eluted from the column and detected before
homoduplexes. Most sequence variations yield a unique
elution profile and a characteristic chromatogram pattern.
The precise nature of the sequence variation was determined
by manual, radiolabeled ThermoSequenase sequencing
(Amersham Life Science, Cleveland, Ohio) and indepen-
dently confirmed by dye-terminator cycle-sequencing (ABI
Prism 377) (31).
Mutations are denoted using accepted nomenclature (32).
For proteins, the single letter amino acid code is utilized. To
indicate an amino acid missense mutation, the format
R403Q is used. Here, the “wild-type” amino acid (R 
arginine) is given before and the mutant amino acid (Q 
glutamine) is provided after the codon number , 403.
R403Q mutation-specific DdeI restriction enzyme assay.
DdeI restriction enzyme digests were performed to screen
for the R403Q mutation in MYH7. Restriction digests were
performed on PCR products for 2 h at 37°C, and then the
digests were analyzed on a 3% agarose gel.
Statistical analysis. Tests for associations between the
presence or absence of malignant mutations and clinical
variables (i.e., gender, age-dependence, left ventricular wall
thickness [LVWT]) were performed with Fisher exact test
for categorical variables and the Wilcoxon-Mann-Whitney
test for continuous and ordered variables. Reported p values
are two-sided, and a p value0.05 is considered statistically
significant.
RESULTS
Table 1 summarizes the demographics of this HCM cohort.
Between April 1997 and October 2000, 293 unrelated
individuals diagnosed with HCM were seen at the HCM
Clinic and investigated for the presence of a “malignant”
mutation. Over half of the patients sought medical evalua-
tion because of the presence of cardiac symptoms including
angina, syncope, dyspnea or out-of-hospital cardiac arrest
(n  160, 54.6%). The remaining patients were diagnosed
during evaluation of a family history of HCM, SCD or
during a routine medical evaluation. A positive family
history for HCM was elicited in 95 patients (32.4%). A total
of 69 patients (23.5%) had a family history of at least one
Abbreviations and Acronyms
DHPLC  denaturing high-performance liquid
chromatography
DNA  deoxyribonucleic acid
HCM  hypertrophic cardiomyopathy
ICD  implanted cardioverter defibrillator
LVOTO  left ventricular outflow tract obstruction
LVWT  left ventricular wall thickness
MYH7  cardiac beta-myosin heavy chain
PCR  polymerase chain reaction
SCD  sudden cardiac death
TNNT2  troponin T
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SCD before the age of 40. Overall, 40 patients (13.7%)
presented with cardiac symptoms and a positive family
history of SCD. The average age at diagnosis was 42.5
years. A total of 53 patients (18%) were diagnosed with
HCM before age 25.
Figure 1 displays the anatomic phenotype of HCM
expressed in this cohort. A total of 155 patients (53%) had
“typical” HCM characterized by asymmetric septal hyper-
trophy and resting left ventricular outflow tract obstruction
(LVOTO). In this subset with resting obstruction, the peak
gradient at rest was approximately 60 mm Hg. For the
entire cohort, the average maximal LVWT was 21 mm. The
greatest LVWT recorded was 46 mm. A total of 18 patients
(6.1%) had extreme hypertrophy (LVWT 30 mm). With
respect to therapies rendered, 83 patients (28.3%) had a
surgical myectomy, and 25 patients (8.5%) had received an
ICD.
Malignant mutations. Only 3 of 293 patients (1%) were
found to possess one of the previously published “malig-
nant” mutations (Fig. 2A to 2C). All three individuals
harboring a malignant mutation were diagnosed with HCM
before age 25 (3/53 vs. 0/240, p  0.006). Table 2
summarizes the clinical profiles of the three patients found
to possess a “malignant” mutation.
None of the 293 patients had the R403Q mutation by
DHPLC. The absence of this specific mutation in this
HCM cohort was confirmed using a mutation-specific
restriction enzyme assay (data not shown). No patients were
identified with the R719W mutation either. However, one
patient had a published R719Q mutation indicating that
DHPLC can resolve sequence variations at this site (data
not shown).
Case 1. The R453C-MHY7 defect was found in an 11-
year-old male patient despite no family history of HCM or
sudden death (Fig. 2A). He was diagnosed during infancy
after evaluation of a murmur. Calcium channel and beta-
blocker therapy was initiated at age 8 after serial observation
of increasing LVWT. He had extreme hypertrophy (38-mm
septum) with maximal obstruction extending 4 cm below
the aortic valve. At 11 years of age, a surgical myectomy was
attempted, but the gradient was not eliminated completely.
Two months later, he had a documented episode of symp-
tomatic ventricular tachycardia. He was re-evaluated, and
ventricular tachycardia was induced during an electrophys-
iology study. An ICD was implanted in March 2000. Thus
far, there have been no shocks delivered.
Case 2. The G716R-MYH7 defect was found in a 32-year-
old man with a strong family history of both HCM and
SCD (Fig. 2B). He was known to have a murmur in
childhood and was diagnosed with obstructive HCM in his
early 20s after presenting with palpitations. He has never
had a syncopal episode. Of his 10 siblings, 4 have echocar-
diographic documentation of obstructive HCM with asym-
metric septal hypertrophy. There have been three sudden
deaths in his immediate family including his mother at age
46 and two sisters—ages 16 and 42. His echocardiogram
demonstrates a resting gradient of 77 mm Hg and severe
septal hypertrophy with a maximal LVWT of 26 mm. He is
now on beta-blockers and has received an ICD as primary
prevention.
Case 3. A third patient possessed the R92W-TNNT2
mutation (Fig. 2C). This 24-year-old woman was diagnosed
at 20 years of age after experiencing palpitations and mild
Table 1. Demographics of HCM Cohort (n  293)
Age at diagnosis (yrs) (range) 42.5  18.9 (0–89.5)
Gender (male/female) 156/137
Mean LVWT (mm) (range) 21  6 (15–46)
Peak resting gradient (mm Hg) (range) 60.4  40 (4–231)
# of patients presenting with cardiac symptoms 160 (54.6%)
# of patients with a positive family history
of HCM
95 (32.4%)
# of patients with a positive family history
of SCD
69 (23.5%)
# of patients treated with surgical myectomy 83 (28.3%)
# of patients implanted with an ICD 25 (8.5%)
HCM  hypertrophic cardiomyopathy; ICD  implanted cardioverter defibrillator;
LVWT  left ventricular wall thickness; SCD  sudden cardiac death.
Figure 1. Morphology of hypertrophic cardiomyopathy (HCM). Anatomical phenotype of HCM seen in this cohort is depicted. A total of 155 of the
patients (53%) had HCM characterized by asymmetric septal hypertrophy and left ventricular outflow tract obstruction (LVOTO). Apical  no gradient
and hypertrophy predominantly in the distal one-third of the left ventricle (LV); HCM with LVOTO  resting gradient 50 mm Hg; Mid-cavitary
obstruction  dynamic obstruction at the level of papillary muscle head or deeper within the LV cavity; Labile  resting gradient 50 mm Hg but
provokable to 50 mm Hg with either Valsalva maneuver or amyl nitrite; Non-obstructive  no obstruction present at rest or with provocation.
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dyspnea with exercise. Despite her TNNT2 substrate, she
has echocardiographic evidence of extreme hypertrophy
involving the entire septum but without any obstruction
(LVWT  33 mm). There is no family history of SCD.
Her mother was diagnosed clinically with a “mild variant of
HCM” based upon her echocardiogram at age 56. She has
the R92W mutation as well. In contrast to her daughter, the
hypertrophy was mild (16 mm), nonobstructive and local-
ized to the midseptal region.
DISCUSSION
Genetic heterogeneity in HCM. Hypertrophic cardiomy-
opathy is the final common pathway of several different
sarcomeric defects. To date, over 150 mutations have been
reported in nine different genes encoding various elements
of the sarcomere. Mutations are scattered throughout these
genes. Unlike diseases like cystic fibrosis where a single
mutation (F508del) within a single gene (CFTR) causes the
majority of cases, an HCM “hot-spot” does not exist (33). It
would appear that new mutations are being discovered
continually in the nine known HCM-causing genes, and it
is likely that for many families with HCM the specific
disease-causing mutation will be a unique one. In this
respect, our own exon-targeted screening of MYH7 and
TNNT2 revealed four novel mutations (unpublished data,
M. J. Ackerman, January 2001). These factors will limit the
widespread application of a future HCM gene chip con-
taining only those mutations already identified. In addition
to the complexities introduced by genotype-specific inter-
actions with environmental influences and gene modifiers,
significant technological challenges must be surmounted
before routine HCM genotyping using gene chips becomes
a clinical reality.
Malignant versus benign mutations. There is continued
debate over the prognostic significance of HCM causing
mutations. For every genotype-phenotype association there
are exceptions, and these constitute a major impediment to
the use of genotyping alone as a clinical and prognostic tool
for the individual patient. Initially, the four mutations in
MYH7 were assigned the malignant phenotype based on
studies involving a limited number of families: five families
with R403Q, one family with R453C, one family with
G716R and four families with R719W (17,19,20,23,24).
Several exceptions to these associations have been found.
Marian et al. (21) reported a R403Q family where some
affected members had only mild symptoms of HCM.
Another R403Q Korean kindred has been reported having
no SCD in the family (34). The G716R mutation has been
reported in another small family with no history of SCD
(17). The R92W-TNNT2 mutation is associated with
minimal hypertrophy and high risk of SCD (10). However,
in our study, the R92W-TNNT2 proband had extreme
hypertrophy while her similarly affected mother did not, and
there have been no sudden deaths in the family. Other
confounding factors include the variability and phenotypic
expression within individual families, the small size of many
family studies, modifier genes, the role of polymorphisms
and other nongenetic factors. Taken together, these obser-
vations weaken the premise that risk for SCD can be
associated with any certain mutation. We do not yet have
the understanding of HCM necessary to determine which
mutation, combinations of mutations or combinations of
mutations and environmental factors portend an ominous
clinical outcome.
In this study, 1% of the HCM patients possessed one of
the more frequently described “malignant” mutations in-
volving the MYH7 and TNNT2 genes. Interestingly, only
age predicted the presence of one of these “malignant”
mutations. Three of 53 patients 25 years (5.7%) had 1 of
5 “malignant” mutations compared with none of the 240
patients over 25 years. No other factors including degree of
hypertrophy, family history of HCM or sudden death were
associated with this small subset of patients. Of the 40
patients presenting with cardiac symptoms and a family
history of SCD, 1 had a malignant mutation (Case 2). Of
the 18 patients manifesting extreme left ventricular hyper-
trophy (30 mm), malignant mutations were identified in 2
patients. Moreover, the individual with the most significant
number of sudden deaths (4) in the family did not have any
of the five mutations analyzed for in this series. Given the
profound genetic heterogeneity of HCM, the variability of
clinical presentation, despite the same mutation profile, and
the exceedingly low prevalence of “malignant” mutations in
a high-risk tertiary center for HCM, genetic screening is
not an appropriate test for risk assessment.
Study limitations. The proportion of patients in this
cohort with obstructive HCM (53%) is higher than previ-
ously reported in population-based studies. This discrep-
ancy likely stems from our institution’s experience in surgi-
cal myectomy/myotomy and referral patterns for surgical
treatment of LVOTO. Previous reports of TNNT2 muta-
tions indicate a phenotype of minimal hypertrophy (35).
Therefore, TNNT2 mutations may be under-represented in
our cohort.
This study was designed as an antemortem study to
determine the frequency of “malignant” mutations in indi-
viduals still living. The low prevalence of “malignant”
mutations detected may be due to screening a cohort of
HCM patients alive with their disease at an average age at
diagnosis of 42.5 years. In this study, all three patients
having a “malignant” mutation were diagnosed before 25
years of age. However, based upon the published literature,
these “malignant” mutations should have been represented
in our cohort. The life expectancy for individuals with
R403Q (MHY7), R719W (MHY7) and R92W (TNNT2)
mutations was 33 to 38 years old (17,23,25). The mean age
at SCD was 30 years for both R453C and G716R (MHY73)
mutations (19,24). Moreover, 95 individuals in our cohort
had a positive family history of HCM, and 69 probands
had family members who had died suddenly due to their
HCM. However, even in this high-risk subset with a
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Figure 2. “Malignant” mutation detection by denaturing high-performance liquid chromatography. Depicted are the elution profiles for normal samples
and the “malignant” mutations identified in exon 14 (A), exon 19 (B) of the cardiac beta-myosin heavy chain (MHY7) gene and exon 9 (C) of the troponin
T (TNNT2) gene.
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declared malignant phenotype, only 1 of 69 probands (G716R,
1.4%) possessed a “malignant” mutation. The other four
“malignant” mutations were absent in this high-risk subset.
Nonetheless, this patient cohort reflects the individuals
who at presentation are seeking genetic testing for prognos-
tic purposes. Thus, in this patient population, these “ma-
lignant” mutations are rare. Perhaps those individuals har-
boring one of these malignant mutations had already died
and were not represented (35). Only a future study involving
a molecular autopsy for these particular mutations in de-
ceased patients with HCM could determine if there is a
difference in the frequency of these so-called “malignant”
mutations among the living and the dead.
CONCLUSIONS
Hypertrophic cardiomyopathy is the final common pathway
for a large number of sarcomeric perturbations. The exact
mechanisms mitigating hypertrophy and SCD remain un-
known. Although it has been suggested that routine screen-
ing should be done for “malignant” mutations, our evalua-
tion of a tertiary referral population of individuals with
HCM suggests that such a targeted screen will elucidate
very few cases. Informing a patient that they have a “benign”
or “malignant” mutation has serious clinical implications.
Because the genotype/phenotype associations are not un-
equivocally known, the clinical decision to proceed with
Table 2. Patient Profiles
Index
Case
Age/
Gender
Age
at Dx Presentation
LVWT
(mm)
Peak Gradient
(mm Hg)
FH of
HCM
FH of
SCD Treatment(s) Mutation
1 11/M 3 mon murmur 38 70 neg neg myectomy, ICD R453C-MYH7
2 32/M 24 yrs palpitations 26 80 pos pos prophylactic ICD, beta-blocker G716R-MHY7
3 24/F 20 yrs palpitations 33 None pos neg none R92W-TNNT2
Dx  diagnosis; FH  family history; HCM  hypertrophic cardiomyopathy; ICD  internal cardioverter defibrillator; LVWT  left ventricular wall thickness; MYH7 
cardiac beta-myosin heavy chain; SCD  sudden cardiac death; TNNT2  troponin T.
Figure 2. Continued from previous page.
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primary prevention ICD therapy should not consider the
patient’s fundamental disease-causing genetic substrate.
Despite this present limitation in molecular genetic
testing for HCM, yesterday’s unraveling of the molecular
basis for HCM as a primary genetic disease of the sarcomere
combined with new insights from genotype-phenotype
correlative studies have provided the framework for tomor-
row’s improved understanding of the natural history and
prognosis for a patient diagnosed with HCM. Although not
yet a routine clinical test, HCM genotyping is already
making a profound impact in the preclinical diagnosis of
family members where, in fact, the HCM-causing mutation
has been identified. In this situation, an unambiguous
identification of relatives who do or do not possess the
underlying genetic substrate for HCM is not only possible,
but also clinically invaluable.
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